Single-arm clinical trials: EMA launches consultation

General 2 min
April 26, 2023

In contrast to randomised controlled trials (RCTs), single-arm clinical trials (SATs) are relatively simple by design: a sample of individuals receive an experimental treatment for a targeted condition, and are followed over a period of time to observe and evaluate their response to the treatment. RCTs are the gold standard when it comes to evaluating the efficacy of a new treatment, and are vital for marketing authorisation (MA) applications. However, in a distinct subset of MA applications, efficacy data derives from SATs. This is important because for some diseases (rare genetic disorders or cancers, for example), the target population is very small and it may be very difficult (if not impossible) to recruit a sufficient sample population for RCTs.

On 21 April 2023, a draft reflection paper was published by the European Medicines Agency (EMA). The aim of the paper is to consider how SATs are used in MA applications, especially where the SAT provides the pivotal evidence for that application. Although the reflection paper is focused primarily on establishing efficacy, it reaffirms the importance of safety in light of the “substantial shortcomings” of SATs.

The paper helpfully sets out what the EMA considers to be important with respect to design, conduct, interpretation, and assessment of SATs used for MA applications:

  • Choosing an endpoint – these are outcomes that highlight the efficacy of a treatment, such as survival or relief of symptoms.
  • Target and trial population – how to recruit an adequate trial population, especially where the potential impact of unknown diagnostic or predictive variables can not be controlled.
  • Role of external information – how can “extra-study” information be used to interpret the results of the SAT.
  • Statistical principles – how to interpret results accurately and efficiently using statistical best-practice (for example interpreting results, dealing with missing data and sample size considerations ).
  • Source of bias and potential mitigation – how to measure and deal with potential bias in a SAT.

Parties are invited to submit any comments before 30 September 2023. The EMA is expected to reveal the results of the consultation in 2024.

Written by
Phillipus Putter
Phillipus Putter
I am an associate in the Intellectual Property Group based in London. I work with clients on a wide spectrum of intellectual property rights, with a particular focus on patent litigation and enforcement. I have a broad range of contentious and non-contentious experience across all intellectual property rights. Although my main area of focus is patent litigation, I also have a keen interest in trademarks and design rights. My experience includes providing regulatory advice in relation to pharmaceuticals and medical devices, including marketing and advertising of medicinal products in the UK and EU.

Related articles

First medicinal cannabis drug listed on the Australian Pharmaceuticals Benefits Scheme
On 1 May 2021 Epidyolex, the first medicinal cannabis drug product was listed on the Pharmaceutical Benefits...
Bird & Bird secures win in preliminary injunction patent case before the Düsseldorf Courts
On September 26, 2019, the Higher Regional Court of Düsseldorf confirmed on appeal that Teva Pharmaceutical...
More Guidance on Pharma Settlement Agreements from the Court of Justice of the EU (ECJ)
It is clear that under certain specific circumstances, a settlement agreement between a holder of a pharmaceutical...

Leave a comment

Cookie consent
We use analytics cookies to help us understand if our website is working well and to learn what content is most useful to visitors. We also use some cookies which are essential to make our website work. You can accept or reject our analytic cookies (including the collection of associated data) and change your mind at any time. Find out more in our Cookie Notice.